CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer
Por:
Cabrero-de las Heras, S and Martinez-Balibrea, E
Publicada:
14 nov 2018
Resumen:
Colorectal cancer (CRC) is the third most common cancer in men and the second most common cancer in women, worldwide. In the early stages of the disease, biomarkers predicting early relapse would improve survival rates. In metastatic patients, the use of predictive biomarkers could potentially result in more personalized treatments and better outcomes. The CXC family of chemokines (CXCL1 to 17) are small (8 to 10 kDa) secreted proteins that attract neutrophils and lymphocytes. These chemokines signal through chemokine receptors (CXCR) 1 to 8. Several studies have reported that these chemokines and receptors have a role in either the promotion or inhibition of cancer, depending on their capacity to suppress or stimulate the action of the immune system, respectively. In general terms, activation of the CXCR1/CXCR2 pathway or the CXCR4/CXCR7 pathway is associated with tumor aggressiveness and poor prognosis; therefore, the specific inhibition of these receptors is a possible therapeutic strategy. On the other hand, the lesser known CXCR3 and CXCR5 axes are generally considered to be tumor suppressor signaling pathways, and their stimulation has been suggested as a way to fight cancer. These pathways have been studied in tumor tissues (using immunohistochemistry or measuring mRNA levels) or serum [using enzyme-linked immuno sorbent assay (ELISA) or multiplexing techniques], among other sample types. Common variants in genes encoding for the CXC chemokines have also been investigated as possible biomarkers of the disease. This review summarizes the most recent findings on the role of CXC chemokines and their receptors in CRC and discusses their possible value as prognostic or predictive biomarkers as well as the possibility of targeting them as a therapeutic strategy.
Filiaciones:
:
Germans Trias & Pujol Hlth Res Inst, Program Canc Therapeut Resistance, Catalan Inst Oncol, Carretera Can Ruti,Cami Escoles S-N, Barcelona 08916, Catalunya, Spain
Germans Trias & Pujol Hlth Res Inst, Program Predict & Personalized Canc Med, Barcelona 08916, Catalunya, Spain
:
Germans Trias & Pujol Hlth Res Inst, Program Canc Therapeut Resistance, Catalan Inst Oncol, Carretera Can Ruti,Cami Escoles S-N, Barcelona 08916, Catalunya, Spain
Germans Trias & Pujol Hlth Res Inst, Program Predict & Personalized Canc Med, Barcelona 08916, Catalunya, Spain
hybrid, Green Published, Green Submitted
|